Sold out

Rozution

Doctor…

Presenting Rosuvees study which is ROSUVastatin trial for Establishing Efficacy and Safety in Indian Hyperlipidemia patients

In Dyslipidemia , CAD patients undergoing PCI & All Diabetic patients

PrescribeRozution… containsRosuvastatin 10/20mg Tablets

“Reduces CVD Risk in Diabetics with Dyslipidemia.”

Description

Doctor…
In Dyslipidemia , CAD patients undergoing PCI & All Diabetic patients
PrescribeRozution… containsRosuvastatin 10/20mg Tablets
“Reduces CVD Risk in Diabetics with Dyslipidemia”

ROSUVastatin trial for Establishing Efficacy and Safety in Indian hyperlipidemia patients.
Methods:
In this multi-Centre, open-label, non-randomized, parallel group study, 219 Indian hyperlipidemic patients were allocated to therapy with either 5, 10 or 20 mg rosuvastatin
Efficacy and safety assessments were performed at weeks 4 and 8 of therapy

Results:
(Rozution) Rosuvastatin 20 mg significantly brings down lipid levels in 8 weeks.
88.8% patients with >2+ risk factors achieved LDL-c targets & improved atherogenic lipid profile.
Conclusion:
In patients with higher cardiovascular risk profile, (Rozution) rosuvastatin 10 and 20 mg are more effective starting doses for quicker achievement of NCEP-ATP III-defined lipid goals.

Thus doctor, to all your patients with In Dyslipidemia , CAD patients undergoing PCI & All Diabetic patients PrescribeRozution contains
Rosuvastatin 10/20mg Tablets
“Reduces CVD Risk in Diabetics with Dyslipidemia”